$LAB
STANDARD BIOTOOLS INC. Stock $lab

$lab Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000095017024122473 Filed on November 06, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$44.97M	$25.37M
YoY Change		77.27%	-1.09%
Cost Of Revenue		$21.71M	$14.21M
YoY Change		52.73%	-13.47%
Gross Profit		$23.26M	$11.15M
YoY Change		108.54%	20.98%
Gross Profit Margin		51.73%	43.97%
Selling, General & Admin		$34.40M	$22.29M
YoY Change		54.33%	-24.68%
% of Gross Profit		147.9%	199.86%
Research & Development		$13.16M	$6.370M
YoY Change		106.53%	-26.36%
% of Gross Profit		56.56%	57.11%
Depreciation & Amortization		$3.858M	$3.980M
YoY Change		-3.07%	10.49%
% of Gross Profit		16.59%	35.68%
Operating Expenses		$54.98M	$32.33M
YoY Change		70.08%	-40.87%
Operating Profit		-$31.72M	-$21.17M
YoY Change		49.81%	-27.06%
Interest Expense		$3.941M	$1.223M
YoY Change		222.24%	16.59%
% of Operating Profit
Other Income/Expense, Net		$957.0K	$1.448M
YoY Change		-33.91%	-770.37%
Pretax Income		-$26.82M	-$20.95M
YoY Change		28.04%	-30.5%
Income Tax		$100.0K	$100.0K
% Of Pretax Income
Net Earnings		-$26.94M	-$21.00M
YoY Change		28.29%	-28.64%
Net Earnings / Revenue		-59.9%	-82.77%
Basic Earnings Per Share		-$0.07	-$0.27
Diluted Earnings Per Share		-$0.07	-$0.27
COMMON SHARES
Basic Shares Outstanding	372.3M	371.2M	78.96M shares
Diluted Shares Outstanding		371.5M	79.15M

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$366.3M	$128.9M
YoY Change	184.31%	-30.41%
Cash & Equivalents	$210.6M	$79.66M
Short-Term Investments	$155.7M	$49.20M
Other Short-Term Assets	$9.316M	$3.400M
YoY Change	174.0%	-26.23%
Inventory	$42.64M	$21.93M
Prepaid Expenses
Receivables	$35.32M	$16.56M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$453.6M	$170.7M
YoY Change	165.67%	-25.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$41.98M	$24.54M
YoY Change	71.09%	-7.7%
Goodwill	$106.3M	$106.2M
YoY Change	0.11%	0.15%
Intangibles	$23.37M	$4.200M
YoY Change	456.36%	-72.73%
Long-Term Investments
YoY Change
Other Assets	$4.640M	$2.390M
YoY Change	94.14%	-23.37%
Total Long-Term Assets	$227.9M	$168.5M
YoY Change	35.24%	-9.34%
TOTAL ASSETS
Total Short-Term Assets	$453.6M	$170.7M
Total Long-Term Assets	$227.9M	$168.5M
Total Assets	$681.5M	$339.3M
YoY Change	100.88%	-18.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.93M	$7.327M
YoY Change	49.12%	-21.26%
Accrued Expenses	$31.69M	$10.20M
YoY Change	210.68%	47.51%
Deferred Revenue	$13.44M	$11.23M
YoY Change	19.6%	-0.78%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$54.91M	$5.000M
YoY Change	998.26%	500.24%
Total Short-Term Liabilities	$120.6M	$51.80M
YoY Change	132.85%	12.2%
LONG-TERM LIABILITIES
Long-Term Debt	$299.0K	$59.60M
YoY Change	-99.5%	-6.71%
Other Long-Term Liabilities	$1.510M	$1.086M
YoY Change	39.04%	-7.26%
Total Long-Term Liabilities	$1.510M	$1.086M
YoY Change	39.04%	-7.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$120.6M	$51.80M
Total Long-Term Liabilities	$1.510M	$1.086M
Total Liabilities	$192.2M	$159.8M
YoY Change	20.32%	-4.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.152B	-$981.0M
YoY Change	17.39%	8.37%
Common Stock	$390.0K	$82.00K
YoY Change	375.61%	3.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$489.3M	-$131.7M
YoY Change
Total Liabilities & Shareholders Equity	$681.5M	$339.3M
YoY Change	100.88%	-18.23%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$26.94M	-$21.00M
YoY Change	28.29%	-28.64%
Depreciation, Depletion And Amortization	$3.858M	$3.980M
YoY Change	-3.07%	10.49%
Cash From Operating Activities	-$27.87M	-$11.42M
YoY Change	144.04%	-53.6%
INVESTING ACTIVITIES
Capital Expenditures	$2.255M	$900.0K
YoY Change	150.56%	-171.2%
Acquisitions
YoY Change
Other Investing Activities	-$28.63M	-$49.02M
YoY Change	-41.6%	-508.5%
Cash From Investing Activities	-$30.88M	-$49.93M
YoY Change	-38.15%	-565.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.000K	-1.170M
YoY Change	-99.83%	23300.0%
NET CHANGE
Cash From Operating Activities	-27.87M	-11.42M
Cash From Investing Activities	-30.88M	-49.93M
Cash From Financing Activities	-2.000K	-1.170M
Net Change In Cash	-58.75M	-62.52M
YoY Change	-6.02%	350.43%
FREE CASH FLOW
Cash From Operating Activities	-$27.87M	-$11.42M
Capital Expenditures	$2.255M	$900.0K
Free Cash Flow	-$30.12M	-$12.32M
YoY Change	144.51%	-47.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosed in the accompanying notes. Actual results could differ materially from these estimates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant estimates and assumptions which form the basis of amounts reported in the condensed consolidated financial statements include, but are not limited to, the identification of performance obligations in contracts with customers; standalone selling prices of the Company's performance obligations; timing of revenue recognition; fair value measurements; net realizable value of inventory; income taxes; and the fair value of intangible assets acquired in business combinations. The Company bases its estimates on current facts and circumstances, historical experience, forecasted results, and various other assumptions that it believes to be reasonable. The Company obtains reports from third-party valuation experts to inform and support estimates related to certain fair value measurements.</span></p>
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001162194
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P6M
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-34180
	dei	Entity Registrant Name EntityRegistrantName	STANDARD BIOTOOLS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0513190
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Tower Place
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2000
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	266-6000
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	LAB
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	372258798
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	210647000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51704000
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	155683000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	63191000
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35317000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19660000
CY2024Q3	us-gaap	Inventory Net InventoryNet	42644000
CY2023Q4	us-gaap	Inventory Net InventoryNet	20533000
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9316000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3127000
CY2024Q3	us-gaap	Assets Current AssetsCurrent	453607000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	158215000
CY2024Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	17949000
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	0
CY2024Q3	lab	Royalty Receivable Non Current RoyaltyReceivableNonCurrent	3388000
CY2023Q4	lab	Royalty Receivable Non Current RoyaltyReceivableNonCurrent	0
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41982000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24187000
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30264000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30663000
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4640000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2285000
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23367000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1400000
CY2024Q3	us-gaap	Goodwill Goodwill	106342000
CY2023Q4	us-gaap	Goodwill Goodwill	106317000
CY2024Q3	us-gaap	Assets Assets	681539000
CY2023Q4	us-gaap	Assets Assets	323067000
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	10926000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9236000
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31686000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21019000
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6122000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4323000
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13436000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11607000
CY2024Q3	lab	Deferred Grant Revenue Current DeferredGrantRevenueCurrent	3532000
CY2023Q4	lab	Deferred Grant Revenue Current DeferredGrantRevenueCurrent	3612000
CY2024Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	0
CY2023Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	5000000
CY2024Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	54913000
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	54530000
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	120615000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	109327000
CY2024Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	299000
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	569000
CY2024Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0
CY2023Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	3414000
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	841000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	841000
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28140000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30374000
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	32682000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3520000
CY2024Q3	lab	Deferred Grant Revenue Noncurrent DeferredGrantRevenueNoncurrent	8119000
CY2023Q4	lab	Deferred Grant Revenue Noncurrent DeferredGrantRevenueNoncurrent	10755000
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1510000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1065000
CY2024Q3	us-gaap	Liabilities Liabilities	192206000
CY2023Q4	us-gaap	Liabilities Liabilities	159865000
	lab	Amortizes Internal Use Software Costs Using Straight Line Method AmortizesInternalUseSoftwareCostsUsingStraightLineMethod	P3Y
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2024Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0
CY2024Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2024Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	256000
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	256000
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	256000
CY2024Q3	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0
CY2023Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	255559000
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	311253000
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	9744000
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	390841000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83364000
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	372261000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	80232000
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	390000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	83000
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1688398000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	860816000
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1409000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2221000
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1151579000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1000752000
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	18580000
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	3132000
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	46467000
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	5977000
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	489333000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-148051000
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	681539000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	323067000
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44969000
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25367000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	127714000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	78152000
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21708000
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14213000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	65357000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	41059000
CY2024Q3	us-gaap	Gross Profit GrossProfit	23261000
CY2023Q3	us-gaap	Gross Profit GrossProfit	11154000
	us-gaap	Gross Profit GrossProfit	62357000
	us-gaap	Gross Profit GrossProfit	37093000
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13156000
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6370000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48358000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19039000
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34403000
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22292000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	119020000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	66187000
CY2024Q3	us-gaap	Restructuring Charges RestructuringCharges	2341000
CY2023Q3	us-gaap	Restructuring Charges RestructuringCharges	1998000
	us-gaap	Restructuring Charges RestructuringCharges	12374000
	us-gaap	Restructuring Charges RestructuringCharges	5415000
CY2024Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	5079000
CY2023Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1666000
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	25024000
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1666000
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	54979000
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	32326000
	us-gaap	Operating Expenses OperatingExpenses	204776000
	us-gaap	Operating Expenses OperatingExpenses	92307000
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-31718000
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-21172000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-142419000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-55214000
CY2024Q3	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0
CY2023Q3	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0
	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	25213000
	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0
CY2024Q3	us-gaap	Interest Income Operating InterestIncomeOperating	3941000
CY2023Q3	us-gaap	Interest Income Operating InterestIncomeOperating	340000
	us-gaap	Interest Income Operating InterestIncomeOperating	13559000
	us-gaap	Interest Income Operating InterestIncomeOperating	656000
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	957000
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-115000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-865000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	292000
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26820000
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20947000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-104512000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54266000
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	118000
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	50000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	301000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	614000
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-26938000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-20997000
	us-gaap	Net Income Loss NetIncomeLoss	-104813000
	us-gaap	Net Income Loss NetIncomeLoss	-54880000
CY2024Q3	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	0
CY2023Q3	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	0
	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	46014000
	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	0
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26938000
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20997000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-150827000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-54880000
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	371538000
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	371538000
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79152000
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79152000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	346093000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	346093000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78967000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78967000
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-26938000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-20997000
	us-gaap	Net Income Loss NetIncomeLoss	-104813000
	us-gaap	Net Income Loss NetIncomeLoss	-54880000
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-304000
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-403000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	540000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-560000
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	395000
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	5000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	272000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	507000
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	91000
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-398000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	812000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-53000
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26847000
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21395000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-104001000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54933000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-148051000
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	311253000
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-18000
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	72000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11611000
CY2024Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	11051000
CY2024Q1	lab	Common Stock Relinquished In Litigation Settlement CommonStockRelinquishedInLitigationSettlement	1009000
CY2024Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	444219000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-32157000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	429000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	577316000
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-326000
CY2024Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	425000
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	981000
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6730000
CY2024Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	29439000
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-45718000
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	292000
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	510261000
CY2024Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-70000
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	68000
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5921000
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-26938000
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	91000
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	489333000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-81467000
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-93000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3148000
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2466000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16843000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	568000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-97153000
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-36000
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	326000
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3114000
CY2023Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2375000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-17040000
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-223000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-113387000
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-11000
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	86000
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3386000
CY2023Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	399000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-20997000
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-398000
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-131720000
	us-gaap	Net Income Loss NetIncomeLoss	-104813000
	us-gaap	Net Income Loss NetIncomeLoss	-54880000
	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	25213000
	us-gaap	Share Based Compensation ShareBasedCompensation	24262000
	us-gaap	Share Based Compensation ShareBasedCompensation	9648000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3533000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8400000
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	9375000
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	2874000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	6303000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	321000
	lab	Non Cash Lease Expense NonCashLeaseExpense	4348000
	lab	Non Cash Lease Expense NonCashLeaseExpense	2885000
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	1991000
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	963000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-474000
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1111000
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	611000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2272000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-677000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14910000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3258000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2718000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-749000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-12887000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-484000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3450000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5448000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3572000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	218000
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4414000
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2802000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-4433000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	46000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-129395000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29226000
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	280033000
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	226612000
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	55857000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	289000000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	91964000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4973000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2753000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	337448000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	33354000
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	8192000
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	833000
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	545000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	40490000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	5240000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	425000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	326000
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	414000
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	139000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1120000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	80000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-48096000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5806000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-518000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-196000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	159439000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1874000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52499000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82324000
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	211938000
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80450000
	lab	Equity Consideration Transferred In Connection With Merger EquityConsiderationTransferredInConnectionWithMerger	444219000
	us-gaap	Interest Paid Net InterestPaidNet	1644000
	us-gaap	Interest Paid Net InterestPaidNet	2171000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	407000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	629000
	lab	Non Cash Right Of Use Assets And Lease Liabilities NonCashRightOfUseAssetsAndLeaseLiabilities	183000
	lab	Non Cash Right Of Use Assets And Lease Liabilities NonCashRightOfUseAssetsAndLeaseLiabilities	226000
	lab	Asset Retirement Obligations Incurred But Not Yet Paid AssetRetirementObligationsIncurredButNotYetPaid	777000
	lab	Asset Retirement Obligations Incurred But Not Yet Paid AssetRetirementObligationsIncurredButNotYetPaid	739000
CY2024Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	44969000
CY2023Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	47415000
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	128359000
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	141047000
CY2024Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-26938000
CY2023Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-41204000
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-134607000
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-109000000
	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	61500000
	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	30600000
CY2024Q3	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	22900000
CY2024Q3	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	1600000
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44969000
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25367000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	127714000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	78152000
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44969000
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25367000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	127714000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	78152000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15127000
	us-gaap	Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination	34189000
	lab	Contract With Customer Revenue Recognized ContractWithCustomerRevenueRecognized	-12552000
	lab	Contract With Customer Revenue Recognized Net ContractWithCustomerRevenueRecognizedNet	9354000
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	46118000
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	4321000
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	9002000
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3678000
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1790000
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	18791000
CY2023Q4	us-gaap	Goodwill Goodwill	106317000
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	25000
CY2024Q3	us-gaap	Goodwill Goodwill	106342000
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	142914000
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	119547000
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	23367000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	117354000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	115954000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1400000
CY2024Q3	lab	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	700000
CY2023Q3	lab	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	2800000
	lab	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	3500000
	lab	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	8400000
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	711000
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2844000
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2844000
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2844000
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2844000
CY2024Q3	lab	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	11280000
CY2024Q3	lab	Finite Lived Intangible Assets Future Expected Amortization Expense FiniteLivedIntangibleAssetsFutureExpectedAmortizationExpense	23367000
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	210647000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51704000
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1291000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	795000
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	211938000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52499000
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1300000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000
CY2024Q3	lab	Trade Receivables TradeReceivables	35337000
CY2023Q4	lab	Trade Receivables TradeReceivables	19972000
CY2024Q3	lab	Royalty Receivable Current RoyaltyReceivableCurrent	435000
CY2023Q4	lab	Royalty Receivable Current RoyaltyReceivableCurrent	0
CY2024Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	173000
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	0
CY2024Q3	lab	Allowance For Expected Credit Losses AllowanceForExpectedCreditLosses	-628000
CY2023Q4	lab	Allowance For Expected Credit Losses AllowanceForExpectedCreditLosses	-312000
CY2024Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	35317000
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	19660000
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	49953000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	12140000
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1558000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	282000
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9082000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8111000
CY2024Q3	us-gaap	Inventory Gross InventoryGross	60593000
CY2023Q4	us-gaap	Inventory Gross InventoryGross	20533000
CY2024Q3	lab	Inventory Current InventoryCurrent	42644000
CY2023Q4	lab	Inventory Current InventoryCurrent	20533000
CY2024Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	17949000
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	0
CY2024Q3	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	100000
CY2023Q3	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	400000
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	2000000
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	1000000
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	105382000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	57342000
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	69623000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	35489000
CY2024Q3	us-gaap	Construction In Progress Gross ConstructionInProgressGross	6223000
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2334000
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41982000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24187000
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3200000
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1200000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9400000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2900000
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14390000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12052000
CY2024Q3	lab	Loss Contingency Accruals LossContingencyAccruals	4262000
CY2023Q4	lab	Loss Contingency Accruals LossContingencyAccruals	0
CY2024Q3	lab	Accrued Warranties Current AccruedWarrantiesCurrent	1874000
CY2023Q4	lab	Accrued Warranties Current AccruedWarrantiesCurrent	2593000
CY2024Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	2541000
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	825000
CY2024Q3	lab	Accrued Uninvoiced Receipts Current AccruedUninvoicedReceiptsCurrent	1354000
CY2023Q4	lab	Accrued Uninvoiced Receipts Current AccruedUninvoicedReceiptsCurrent	1516000
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7265000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4033000
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31686000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21019000
CY2020Q3	lab	Research And Development Arrangement Contract To Perform For Others Maximum Contract Value ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue	34000000
CY2020Q3	lab	Research And Development Arrangement Contract To Perform For Others Capital Expenditures ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpenditures	22200000
CY2024Q3	lab	Research And Development Arrangement Contract To Perform For Others Depreciation Expense ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense	900000
CY2023Q3	lab	Research And Development Arrangement Contract To Perform For Others Depreciation Expense ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense	900000
	lab	Research And Development Arrangement Contract To Perform For Others Depreciation Expense ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense	2700000
	lab	Research And Development Arrangement Contract To Perform For Others Depreciation Expense ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense	2700000
CY2024Q3	lab	Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses	10500000
CY2023Q4	lab	Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses	7800000
CY2024Q3	lab	Research And Development Arrangement Contract To Perform For Others Property And Equipment Net ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet	11700000
CY2023Q4	lab	Research And Development Arrangement Contract To Perform For Others Property And Equipment Net ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet	14400000
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	55212000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	63513000
	lab	Number Of Leases For Office And Laboratory Space NumberOfLeasesForOfficeAndLaboratorySpace	3
	lab	Lessee Operating Lease Assumed Lease Expired LesseeOperatingLeaseAssumedLeaseExpired	2024-06-30
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	extend the leases
	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	2386000
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1994000
	us-gaap	Operating Lease Cost OperatingLeaseCost	7484000
	us-gaap	Operating Lease Cost OperatingLeaseCost	6005000
CY2024Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2023Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	1188000
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	830000
	us-gaap	Variable Lease Cost VariableLeaseCost	3781000
	us-gaap	Variable Lease Cost VariableLeaseCost	2417000
CY2024Q3	us-gaap	Sublease Income SubleaseIncome	1076000
CY2023Q3	us-gaap	Sublease Income SubleaseIncome	529000
	us-gaap	Sublease Income SubleaseIncome	3228000
	us-gaap	Sublease Income SubleaseIncome	1978000
CY2024Q3	us-gaap	Lease Cost LeaseCost	2498000
CY2023Q3	us-gaap	Lease Cost LeaseCost	2295000
	us-gaap	Lease Cost LeaseCost	8037000
	us-gaap	Lease Cost LeaseCost	6444000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2419000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9789000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8800000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7428000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7362000
CY2024Q3	lab	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	10225000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	46023000
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11761000
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	34262000
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6122000
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28140000
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.119
CY2024Q3	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	16200000
CY2024Q1	lab	Settled Outstanding Litigation SettledOutstandingLitigation	422048
CY2024Q2	lab	Settlement Of Outstanding Litigation SettlementOfOutstandingLitigation	6200000
CY2024Q2	lab	Repurchase Of Common Stock Shares For Litigation Settlement RepurchaseOfCommonStockSharesForLitigationSettlement	1840000
CY2024Q2	us-gaap	Share Price SharePrice	2.4
CY2024Q2	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	1800000
	us-gaap	Litigation Settlement Loss LitigationSettlementLoss	600000
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	340562000
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	348000
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	340910000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	98554000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	98576000
CY2024Q3	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss	0
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0
CY2024Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	906
	lab	Change In Fair Value Of Warrant Liabilities Recurring Basis ChangeInFairValueOfWarrantLiabilitiesRecurringBasis	474
CY2024Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	432
CY2024Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	25419000
	lab	Merger Exchange Ratio MergerExchangeRatio	0.0111
	lab	Stock Based Compensation Expense Due To Acceleration Of Awards StockBasedCompensationExpenseDueToAccelerationOfAwards	6200000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9294
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.62
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M
	lab	Stock Options Assumed Through Acquisition StockOptionsAssumedThroughAcquisition	28184
	lab	Stock Options Assumed Weighted Average Exercise Price StockOptionsAssumedWeightedAverageExercisePrice	4.8
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	6697
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.5
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	573
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.12
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3374
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.92
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	40228
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.26
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y2M12D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	196
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	28006
CY2024Q3	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	4.76
	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTermOne	P5Y1M6D
CY2024Q3	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue	93
	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber	12222
CY2024Q3	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice	3.1
	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm1	P8Y8M12D
CY2024Q3	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	103
CY2024Q3	us-gaap	Share Price SharePrice	1.93
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5921000
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3386000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24262000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9648000
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-26938000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-20997000
	us-gaap	Net Income Loss NetIncomeLoss	-104813000
	us-gaap	Net Income Loss NetIncomeLoss	-54880000
	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	46014000
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26938000
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20997000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-150827000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-54880000
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	371538000
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	371538000
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79152000
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79152000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	346093000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	346093000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78967000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78967000
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	54664000
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	16872000
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	75164000
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	11692000
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	85327000
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	111012000
CY2024Q3	lab	Number Of Additional Shares Issuable Under Make Whole Premium Maximum NumberOfAdditionalSharesIssuableUnderMakeWholePremiumMaximum	4741374
CY2023Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	175910
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	15448533
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2634594
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	600000
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44969000
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25367000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	127714000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	78152000
CY2024Q3	us-gaap	Restructuring Charges RestructuringCharges	2341000
CY2023Q3	us-gaap	Restructuring Charges RestructuringCharges	1998000
	us-gaap	Restructuring Charges RestructuringCharges	12374000
	us-gaap	Restructuring Charges RestructuringCharges	5415000
CY2024Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	5079000
CY2023Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1666000
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	25024000
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1666000
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-31718000
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-21172000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-142419000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-55214000
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3858000
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3986000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12908000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11274000
CY2024Q3	us-gaap	Restructuring Charges RestructuringCharges	2300000
	us-gaap	Restructuring Charges RestructuringCharges	12400000
CY2023Q3	us-gaap	Restructuring Charges RestructuringCharges	2000000
	us-gaap	Restructuring Charges RestructuringCharges	5400000
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	825000
	us-gaap	Restructuring Charges RestructuringCharges	12374000
	us-gaap	Payments For Restructuring PaymentsForRestructuring	10658000
CY2024Q3	us-gaap	Restructuring Reserve RestructuringReserve	2541000
CY2023Q3	us-gaap	Restructuring Charges RestructuringCharges	1998000
	us-gaap	Restructuring Charges RestructuringCharges	12374000
	us-gaap	Restructuring Charges RestructuringCharges	5415000
CY2024Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	46465458
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	lab	Rule10 B51 Arr Modified Flag Rule10B51ArrModifiedFlag	false
CY2024Q3	lab	Non Rule10 B51 Arr Modified Flag NonRule10B51ArrModifiedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-24-122473-index-headers.html	Edgar Link	pending
0000950170-24-122473-index.html	Edgar Link	pending
0000950170-24-122473.txt	Edgar Link	pending
0000950170-24-122473-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img187298662_0.jpg	Edgar Link	pending
lab-20240930.htm	Edgar Link	pending
lab-20240930.xsd	Edgar Link	pending
lab-ex31_1.htm	Edgar Link	pending
lab-ex31_2.htm	Edgar Link	pending
lab-ex32_1.htm	Edgar Link	pending
lab-ex32_2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
lab-20240930_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LAB
STANDARD BIOTOOLS INC. Stock $lab

2024 Q4 Form 10-Q Financial Statement

#000095017024122473 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LAB STANDARD BIOTOOLS INC. Stock $lab

2024 Q4 Form 10-Q Financial Statement

#000095017024122473 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LAB
STANDARD BIOTOOLS INC. Stock $lab